Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL) Insider Trading
Directors, officers and holders of more than 10% of ZNTL report their trades in its stock on SEC Form 4, within two business days. Each row below is one Form 4 transaction line. The one-letter code says what kind of transaction it was: only P (purchase) and S (sale) are open-market or private trades; awards, option exercises, tax withholding and gifts carry other codes.
Recent Form 4 transactions
The 50 most recent of 52 transactions on file: 7 with code P, 14 with code S and 29 with other codes.
| Date | Insider | Title | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Bruns Ingmar | Chief Medical Officer | A Award | 9,727 | $2.18 | $21,205 |
| Aug 14, 2026 | WALTERS GROUP | 10% Owner | P Purchase | 4,335,000 | $3.50 | $15,172,500 |
| Jun 16, 2026 | Kariuki Enoch | Director | A Award | 57,100 | Not measured | Not measured |
| Jun 16, 2026 | Johnson David Michael | Director | A Award | 57,100 | Not measured | Not measured |
| Jun 16, 2026 | Myers Scott Dunseth | Director | A Award | 57,100 | Not measured | Not measured |
| Jun 16, 2026 | Walker Luke Nathaniel | Director | A Award | 57,100 | Not measured | Not measured |
| Jun 16, 2026 | Skvarka Jan | Director | A Award | 57,100 | Not measured | Not measured |
| May 26, 2026 | Campbell Shannon | Director | A Award | 114,200 | Not measured | Not measured |
| Feb 10, 2026 | Vultaggio Vincent | PAO and PFO | S Sale | 6,894 | $2.42 | $16,699 |
| Feb 9, 2026 | EASTLAND JULIA MARIE | CEO & President | S Sale | 889 | $2.39 | $2,127 |
| Feb 9, 2026 | Bruns Ingmar | Chief Medical Officer | S Sale | 335 | $2.39 | $802 |
| Feb 9, 2026 | Vultaggio Vincent | PAO and PFO | S Sale | 3,379 | $2.39 | $8,086 |
| Feb 6, 2026 | Bruns Ingmar | Chief Medical Officer | S Sale | 2,962 | $2.43 | $7,197 |
| Feb 6, 2026 | Vultaggio Vincent | PAO and PFO | S Sale | 29,951 | $2.43 | $72,772 |
| Feb 6, 2026 | EASTLAND JULIA MARIE | CEO & President | S Sale | 7,866 | $2.43 | $19,112 |
| Feb 3, 2026 | Vultaggio Vincent | PAO and PFO | S Sale | 556 | $2.52 | $1,398 |
| Feb 2, 2026 | Vultaggio Vincent | PAO and PFO | S Sale | 2,540 | $2.55 | $6,477 |
| Jan 8, 2026 | Bruns Ingmar | Chief Medical Officer | A Award | 365,000 | Not measured | Not measured |
| Jan 8, 2026 | EASTLAND JULIA MARIE | CEO & President | A Award | 775,000 | Not measured | Not measured |
| Jan 8, 2026 | Vultaggio Vincent | PAO and PFO | A Award | 100,000 | Not measured | Not measured |
| Jan 8, 2026 | Bucher James B | Chief Legal Officer | A Award | 100,000 | Not measured | Not measured |
| Dec 31, 2025 | WALTERS GROUP | 10% Owner | P Purchase | 6,459,973 | $1.20 | $7,751,968 |
| Dec 15, 2025 | Matrix Capital Management Company, LP | 10% Owner | S Sale | 7,500,000 | $1.33 | $9,975,000 |
| Oct 1, 2025 | Bucher James B | Chief Legal Officer | A Award | 400,000 | Not measured | Not measured |
| Jun 17, 2025 | Myers Scott Dunseth | Director | A Award | 57,603 | Not measured | Not measured |
| Jun 17, 2025 | Kariuki Enoch | Director | A Award | 57,603 | Not measured | Not measured |
| Jun 17, 2025 | Johnson David Michael | Director | A Award | 57,603 | Not measured | Not measured |
| Jun 17, 2025 | Skvarka Jan | Director | A Award | 57,603 | Not measured | Not measured |
| Jun 17, 2025 | Walker Luke Nathaniel | Director | A Award | 57,603 | Not measured | Not measured |
| Apr 30, 2025 | Myers Scott Dunseth | Director | P Purchase | 21,000 | $1.40 | $29,373 |
| Feb 6, 2025 | Bruns Ingmar | Chief Medical Officer | P Purchase | 20,000 | $2.28 | $45,656 |
| Feb 3, 2025 | Vultaggio Vincent | PAO and PFO | S Sale | 2,615 | $1.71 | $4,476 |
| Feb 3, 2025 | EASTLAND JULIA MARIE | CEO & President | A Award | 59,388 | Not measured | Not measured |
| Feb 3, 2025 | Paul Andrea | Chief Legal Officer | A Award | 124,714 | Not measured | Not measured |
| Feb 3, 2025 | Lackner Mark | Chief Scientific Officer | A Award | 335,907 | Not measured | Not measured |
| Feb 3, 2025 | Lackner Mark | Chief Scientific Officer | S Sale | 14,368 | $1.71 | $24,591 |
| Feb 3, 2025 | Paul Andrea | Chief Legal Officer | A Award | 934,041 | Not measured | Not measured |
| Feb 3, 2025 | Paul Andrea | Chief Legal Officer | S Sale | 13,230 | $1.71 | $22,643 |
| Feb 3, 2025 | Bruns Ingmar | Chief Medical Officer | A Award | 16,629 | Not measured | Not measured |
| Feb 3, 2025 | EASTLAND JULIA MARIE | CEO & President | A Award | 59,388 | Not measured | Not measured |
| Feb 3, 2025 | Vultaggio Vincent | PAO and PFO | A Award | 158,586 | Not measured | Not measured |
| Feb 3, 2025 | Vultaggio Vincent | PAO and PFO | A Award | 35,633 | Not measured | Not measured |
| Feb 3, 2025 | Lackner Mark | Chief Scientific Officer | A Award | 124,714 | Not measured | Not measured |
| Feb 3, 2025 | Bruns Ingmar | Chief Medical Officer | A Award | 16,629 | Not measured | Not measured |
| Jan 31, 2025 | EASTLAND JULIA MARIE | CEO & President | P Purchase | 28,500 | $1.73 | $49,345 |
| Jan 31, 2025 | Skvarka Jan | Director | P Purchase | 60,000 | $1.72 | $103,446 |
| Jan 31, 2025 | Walker Luke Nathaniel | Director | P Purchase | 14,200 | $1.76 | $24,966 |
| Jan 2, 2025 | Lackner Mark | Chief Scientific Officer | S Sale | 4,411 | $3.12 | $13,762 |
| Dec 2, 2024 | EASTLAND JULIA MARIE | CEO & President | A Award | 3,028,800 | Not measured | Not measured |
| Dec 2, 2024 | Bruns Ingmar | Chief Medical Officer | A Award | 712,650 | Not measured | Not measured |
The full Form 4 history is on the ZNTL company page (Insider Trades card, View all).
Questions about this data
Which insider transactions are open-market trades?
Code P (open market or private purchase) and code S (open market or private sale). Code F is shares withheld to pay tax on vesting stock, A is an award from the company, M and X are option exercises and G is a gift. None of those is the insider choosing to buy or sell in the market.
How quickly are insider trades reported?
A Form 4 is due before the end of the second business day after the trade. The date shown is the transaction date from the form.
Who has to file Form 4?
Officers, directors and beneficial owners of more than 10% of a class of the company’s registered equity, under Section 16 of the Securities Exchange Act.
Look up any code in the Form 4 transaction code reference, or read Form 4 codes explained.